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Abstract
Background: As an obligatory intracellular parasite, Trypanosoma cruzi, the etiological agent of
Chagas' disease, must invade and multiply within mammalian cells. Cytokeratin 18 (CK18) is among
the host molecules that have been suggested as a mediator of important events during T. cruzi-host
cell interaction. Based on that possibility, we addressed whether RNA interference (RNAi)-
mediated down regulation of the CK18 gene could interfere with the parasite life cycle in vitro. HeLa
cells transiently transfected with CK18-RNAi had negligible levels of CK18 transcripts, and
significantly reduced levels of CK18 protein expression as determined by immunoblotting or
immunofluorescence.
Results: CK18 negative or positive HeLa cells were invaded equally as well by trypomastigotes of
different T. cruzi strains. Also, in CK18 negative or positive cells, parasites recruited host cells
lysosomes and escaped from the parasitophorous vacuole equally as well. After that, the growth of
amastigotes of the Y or CL-Brener strains, was drastically arrested in CK18 RNAi-treated cells.
After 48 hours, the number of amastigotes was several times lower in CK18 RNAi-treated cells
when compared to control cells. Simultaneous staining of parasites and CK18 showed that in HeLa
cells infected with the Y strain both co-localize. Although the amastigote surface protein-2 contains
the domain VTVXNVFLYNR previously described to bind to CK18, in several attempts, we failed
to detect binding of a recombinant protein to CK-18.
Conclusion: The study demonstrates that silencing CK18 by transient RNAi, inhibits intracellular
multiplication of the Y and CL strain of T. cruzi in HeLa cells, but not trypanosome binding and
invasion.
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Background
The protozoan parasite Trypanosoma cruzi is the etiologic
agent of Chagas' disease, which chronically affects more
than 10 million individuals in the Americas, with an
annual death toll of approximately 45,000 people [1]. In
spite of the significant reduction in transmission over the
past twenty years in countries such as Argentina, Brazil,
Chile and Uruguay, Chagas' disease is still a major health
problem for many Latin American countries. A recent epi-
demiological study in dogs also revealed a dangerously
widespread epidemic in the state of Texas [2].
The efficacy of conventional chemotherapy with nifurti-
mox or benznidazole is low and varies greatly according
to the infection status of the patients (acute or chronic)
and the parasite strains. Although new drugs could poten-
tially solve the problem, Chagas' disease is one of the
most neglected diseases in terms of drug development
with a single new compound being tested in phase 1/2 tri-
als (reviewed in ref. [3]). Based on these poor short term
prospects, studies aimed at understanding the require-
ments for parasite invasion and multiplication of T. cruzi
are still relevant.
Invasion and multiplication within a variety of host cells
are critical features for the survival of T. cruzi. The invasion
process of mammalian non-phagocytic cells has attracted
a great deal of interest in the past 20 years and notable
advances have been obtained. Different routes of invasion
described by researchers have been mediated by distinct
cell surface receptors, secondary messengers and tran-
scription factors (recently reviewed in refs. [4-6]). In one
of the mechanisms described, the infective forms of T.
cruzi  (trypomastigotes) take advantage of a host cell
mechanism for puncture repair and exocytosis of lyso-
somes to recruit these organelles to the parasite-cell junc-
tion. After a Ca2+  dependent fusion with the cell
membrane, lysosomes become part of the intracellular
parasitophorous vacuole. Alternatively, parasites can use a
lysosome-independent pathway. In this case, the host cell
plasma membrane accounts for the parasitophorus vacu-
ole. Ultimately, these organelles fuse with lysosomes, a
step that recently has been shown to be critical for parasite
retention and productive infection [7]. Among the para-
site surface molecules that might be relevant for the
attachment, signaling and penetration are members of a
family of mucin-like glycoproteins, members of a trans-
sialidases family, and proteases (reviewed in ref. [8-10]).
Once inside the host cells, T. cruzi manages to disrupt the
parasitophorus vacuole, an event that could be mediated
by lytic proteins and the enzyme trans-sialidase [11-14].
During the escape, trypomastigotes transform into amas-
tigotes and express on its surface some stage-specific mol-
ecules [15-17]. In the host cell cytoplasm, GPI-deficient
amastigotes arrest replication and subsequently failed to
differentiate into trypomastigotes [18]. The molecular
events required for amastigote transformation into trypo-
mastigotes and their release from the infected cells are
completely unknown.
The accessibility of the new reverse genetic tools such as
RNAi have allowed investigators to search for host mole-
cules that might be important for the T. cruzi invasion as
well as intracellular parasite survival and multiplication.
Villalta's group demonstrated that the silencing of lam-
inin-γ1 expression, a protein belonging to the extracellu-
lar matrix and regulated by the parasite, by cultured
human coronary artery smooth muscle cells rendered
them significantly more resistant to the binding and pen-
etration of parasites (reviewed in [5,6,19]). This observa-
tion supports the hypothesis that the binding to laminin
is an important step for the early process of T. cruzi infec-
tion. Also, it suggests that laminin-binding proteins
expressed on the surface of T. cruzi are important virulence
factors during the infection of human smooth muscle
cells [5,6,19,20]. Utilizing a similar approach, the same
group demonstrated that stable interference of throm-
bospondin-1 expression, also a protein belonging to the
extracellular matrix, in cultured HeLa cells in vitro caused
an increase in the cell resistance to T. cruzi invasion
[5,6,21]. These studies demonstrated the effectiveness of
the RNAi strategy when studying the host cell factors crit-
ical for parasite survival and eventually identifying poten-
tial targets for new therapies.
One of the laminin-binding proteins, a member of the
family of the trans-sialidases of T. cruzi (Tc-85-11), was
shown to bind to host cytokeratin 18 (CK18). The CK18
is an intermediate filament protein of the acid cytokeratin
family belonging to type I, expressed in the internal epi-
thelia cell cytoplasm. This protein together with CK8
exhibit resistance features in response to other forms of
stress and to apoptosis [22]. This interaction through a C-
terminal peptide ligand denominated FLY domain
(VTVXNVFLYNR, [23]) was shown to be relevant for par-
asite invasion as anti-cytokeratin antibodies inhibited the
infection of epithelial cells by T. cruzi. The FLY motif is not
only present in proteins expressed on the surface of trypo-
mastigotes but also on a protein that is abundant on the
surface of amastigotes denominated Amastigote Surface
Protein-2 (ASP-2, [24,25]). Based on this observation, it
was our intention to further investigate whether the host
cell CK18 expression was indeed critical for T. cruzi inva-
sion and/or subsequent parasite growth in vitro. For this
purpose we used HeLa cells in which we transiently down-
regulated the host CK18 using the RNAi strategy. Upon
infection, we evaluated parasite attachment, penetration,
lysosome recruitment, phagolysosomal escape and cyto-
plasm replication in cultured HeLa cells. RNAi-mediatedBMC Cell Biology 2008, 9:68 http://www.biomedcentral.com/1471-2121/9/68
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knock-down of CK18 did not interfere with trypomastig-
otes mediated events. Once amastigotes from two distinct
strains of T. cruzi were in the cytoplasm of CK18 RNAi-
treated cells, their development was severely inhibited.
Results
RNAi knockdown of endogenous CK18 in cultured HeLa 
cells
Earlier studies have suggested that CK18 plays a role dur-
ing the interaction between trypomastigotes of T. cruzi
and non-phagocytic mammalian cells [23,26]. To further
evaluate whether CK18 expression was indeed critical for
the host parasite interaction, we established an in vitro
transient transfection system to knock down the expres-
sion of endogenous CK18. Following the transfection of
cultured HeLa cells with CK18 RNAi, we evaluated the lev-
els of CK 18-specific transcripts with the aid of quantita-
tive real-time PCR. As shown in Fig. 1A, 24 h following
transfection, the amount of CK18 transcripts were
reduced by more than 40 fold in HeLa cells treated with
CK18 RNAi when compared to control cells untreated or
treated with a control RNAi. The treatment did not modify
the expression of the control housekeeping gene RLP13
used to normalize the level transcript on each sample. We
then studied whether the reduction of CK18 transcripts by
RNAi were reflected at the protein level by quantitative
immunoblotting analysis (Fig. 1B). As estimated by den-
sitometry, the inhibition of CK18 expression was ~70%,
without significant inhibition on the synthesis of β-actin
(Fig. 1C). Finally, we performed an immunofluorescence
based assay to confirm that CK18 expression was inhib-
ited in most cells. As shown in Fig. 1D, HeLa cells tran-
siently transfected with CK18 RNAi and subsequently
infected with trypomastigotes of T. cruzi, had no detecta-
ble fluorescence (Fig. 1Dii). Significant inhibition of
CK18 expression in cultured HeLa cells was maintained
for at least 72 h following transfection (data not shown).
Because CK18 is part of intermediate cell filaments which
also contains large amounts of CK8, we tested whether
CK18 RNAi-treated HeLa cells would also reduce the
expression of stable CK8. Indeed, CK18 RNAi-treatment
reduced the immunofluorescence of HeLa cell stained
with specific anti-CK8 antibodies (Fig 2B). Similar exper-
iments were performed with anti-CK19. In this case we
could not detect CK19 in untreated or CK18 RNAi-treated
HeLa cells (data not shown).
Also, it was possible that the reduction of the levels of this
protein could interfere with cell survival. To evaluate this
possibility, HeLa cells, transfected or not, were kept in cul-
ture for 34 h before cell viability was estimated by staining
with Annexin-V-FITC and PI. As shown in Fig. 3, we did
not observe an increase in the frequency of Annexin-posi-
tive cells when we compared CK18 RNAi-treated or
untreated cells. To confirm Annexin assay results, we
measured the mitochondrial activity by MTT assay, a
method for assessing cell viability by quantifying the con-
version of the tetrazolium salt to its formazan product. We
observed that there was no difference between the CK18
RNAi- treated or control cells (containing only medium or
control RNAi, data not shown). This demonstrates that
RNAi-mediated CK18 knockdown did not promote apop-
tosis.
RNAi-mediated CK18 knockdown impairs amastigote 
replication in the cytoplasm of HeLa cells
CK18 RNAi-treated HeLa cells were initially infected with
tissue culture trypomastigotes of the Y strain of T. cruzi.
After 2 h, cells were washed and fixed. The number of try-
pomastigotes attached, the frequencies of infected cells, as
well as the number of trypomastigotes inside 100 cells
were estimated. We found that all of them were similar in
CK18 RNAi-treated or untreated cells (Fig. 4A, B and 4C,
respectively). We therefore concluded that the reduction
of the CK18 expression did not change the ability of try-
pomastigotes to attach and invade these cells. During the
invasion process, the parasites recruit lysosomes, which
fuse with the parasitophorous vacuoles containing trypo-
mastigotes. Approximately 5 h after infection, more than
90% of the parasites can be co-stained with antibodies
specific for the phagolysosomal marker LAMP-1 (Fig. 5).
After that period, trypomastigotes differentiate and escape
the parasitophorous vacuoles/phagolysosomes. We esti-
mated whether both processes also occur in CK18 RNAi-
treated cells. At different times post-infection, the fre-
quency of parasites co-stained with the phagolysosomal
marker LAMP-1 was similar among infected HeLa cells,
regardless of whether they were transfected with CK18
RNAi (Fig. 5).
Twenty-four hours after infection, no parasites could be
co-stained with anti-LAMP-1 whether they were in the
cytoplasm of CK18 RNAi-treated or non-treated cells. We
then concluded that the reduction of the CK18 expression
did not influence the ability of parasites to recruit the host
cell lysosomes, transform into amastigotes and exit the
parasitophorous vacuoles.
After 24 h, amastigotes were in the host cell cytoplasm
where they began multiplying. When we estimated the fre-
quency of infected cells 48 h after infection, we found that
both CK18 RNAi-treated cells and non-treated HeLa cells
had similar percentages of infected cells (Fig. 6A). Never-
theless, the number of intracellular amastigotes per 100
HeLa cells treated with CK18 RNAi was 79% lower. Con-
sidering that the frequencies of infected cells are lower, we
estimated an inhibition of 85% on the amastigote growth
during the 24 h period (from 24 to 48 h after infection,
Fig. 6B). The impact of CK18 RNAi treatment on parasiteBMC Cell Biology 2008, 9:68 http://www.biomedcentral.com/1471-2121/9/68
Page 4 of 12
(page number not for citation purposes)
CK18 expression on RNAi-treated HeLa cells Figure 1
CK18 expression on RNAi-treated HeLa cells. (A) HeLa cells were left untreated (Medium) or transfected with the 
CK18 or control RNAi as described in the Methods section. CK18 transcripts were estimated by Real-time PCR. Results are 
expressed in arbitrary units after normalization with RPL13 transcritps. Results are represented as an average of triplicate sam-
ples ± SD. The experiments were performed three times with similar results. (B) Immunoblot analysis of HeLa cells extracts 
untreated (Medium) or treated with CK18 or control RNAi. Stainings were performed with MAbs specific for CK18 or β-
actin. (C) Densitometry of immunoblot was performed and the bars represent the absorbance of CK18 bands after normaliza-
tion using the staining with anti-β-actin. (D) IFA staining of HeLa cells untreated (Medium) or treated with CK18 or control 
RNAi. HeLa cells were treated with RNAi for 24 h and infected with tissue culture trypomastigotes for 48 h. After that period, 
cells were stained with a MAbs specific for CK18 (green) and DAPI (blue). Magnification bar = 35 μM.
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growth can be further highlighted by our estimates on the
frequency of infected cells containing 1 to 5 or more than
5 parasites. In the case of CK18 RNAi-treated HeLa cells,
less than 10% of the infected cells had more than 5 para-
sites. In contrast, more than 75% of the infected control
cells were infected with more than 5 amastigotes per cell
(Fig. 6C). Also, we tested the effect of CK18 RNAi treat-
ment on parasite growth in LLC-MK2 cells, after infection
with trypomastigotes of Y strain. As observed in HeLa
cells, the amastigotes growth during the 24 h period (from
24 to 48 h after infection) was dramatically reduced in the
LLC-MK2 cells. While 70% of the CK18 RNAi-treated LLC-
MK2 cells displayed with 1 to 5 parasites, 80% of control
RNAi-treated infected cells had > 5 amastigotes per cell
(data not shown). This suggests that the CK18 RNAi treat-
ment can also impair the amastigotes growth in LLC-MK2
cells.
We then evaluated whether CK18 expression in HeLa cells
was in fact important for the multiplication of amastig-
otes of different T. cruzi strains. To answer this question,
CK18 RNAi-treated HeLa cells were infected with trypo-
mastigotes of Y or CL-Brener strains. After 48 h, the fre-
quency of infected cells and the number of amastigotes
per 100 cells were estimated. As exemplified in Fig. 7,
CK18 RNAi-treated HeLa cells had lower numbers of
amastigotes of Y or CL-Brener strains (Fig. 7C and Fig. 7F).
Table 1 depicts the frequency of infected cells and the
number of amastigotes per 100 cells. The percentages of
infected cells were similar when we compared CK18
RNAi-treated or control HeLa cells. In contrast, the
number of amastigotes of Y or CL-Brener strains per 100
Inhibition of CK8 expression in CK18 RNAi-treated HeLa  cells Figure 2
Inhibition of CK8 expression in CK18 RNAi-treated 
HeLa cells. HeLa cells were treated with medium or trans-
fected with the CK18 RNAi as described in the Methods sec-
tion. After 24 h, cells were stained with a MAbs specific for 
CK8 or CK18 (green) and DAPI (blue). Magnification bar = 
20 μM.
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CK18 RNAi treatment does not cause apoptosis of HeLa cells. HeLa cells were left untreated (Medium) or transfected 
with CK18 or control RNAi. After 34 h, cells were labeled with propidium iodine (PI) and Annexin-V-FITC. Cells were ana-
lyzed by FACS.
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cells was significantly lower in HeLa cells transfected with
CK18 RNAi when compared to controls.
Because reduced levels of CK18 expression are, in some
way, interfering in the intracellular amastigotes growth,
we decide to evaluate whether there was a correlation
between the cellular localization of CK18 and the parasite
after infection. Co-localization experiments are depicted
in Fig. 8. In HeLa cells infected with amatigotes of Y strain,
we observed yellow staining denoting a merge between
the green (CK18) and red (parasite) fluorescences (Fig. 8A
and 8B). Treatment with CK18 RNAi strongly inhibited
CK18 expression and reduced growth of amastigotes of
the Y strain (Fig. 8C).
The experiment of co-localization described above sug-
gested a physical interaction between amastigotes and
HeLa cell's CK18. A putative parasite ligand for CK18 was
described as the highly conserved FLY domain (VTVxNVx-
LYNR). ASP-2 expressed by amastigotes of the Y strain
contains the FLY domain and could be the ligand to the
host cytoplasmatic CK18 [17,24,25]. We performed a
direct binding assay of the ASP-2 recombinant protein of
Y strain (His-65 kDa, [17,25]) to fixed, permeabilized or
CK18 RNAi treatment does not inhibit trypomastigote  attachment or invasion of HeLa cells Figure 4
CK18 RNAi treatment does not inhibit trypomastig-
ote attachment or invasion of HeLa cells. HeLa cells 
were left untreated or treated with CK18 RNAi or control 
RNAi. After 24 h, cells were infected with culture trypomas-
tigotes of the Y strain of T. cruzi. (A) Number of trypomastig-
otes attached to HeLa cells; (B) Frequency of infected HeLa 
cells; (C) Number of parasites per 100 cells. Bars represent 
the average of triplicate cultures ± SD.
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cells were infected with culture trypomastigotes of the Y 
strain of T. cruzi. The frequency of parasites stained with anti-
LAMP-1 MAb is shown at the indicated hours post-infection. 
Dots represent the average of triplicate cultures ± SD.
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not, HeLa cells in vitro. Although MAb to CK-18 strongly
stained permeabilized HeLa cells (positive control), the
recombinant protein His-65 kDa only binds to HeLa cells
fixed but not permeabilized, suggesting a binding to the
surface membrane (data not shown). In any case, we con-
sidered this binding irrelevant to our purposes because it
was not inhibited by CK-18 RNAi treatment of HeLa cells
(data not shown).
Discussion
The present study was designed to evaluate the possible
role of CK18 in the interaction between T. cruzi and non-
phagocytic cells in vitro. The success of the transient
knockdown of CK18 in cultured HeLa cells allowed us to
further investigate for this topic. Unexpectedly, in the
presence of limited amounts of CK18, trypomastigotes
invaded HeLa cells efficiently. In addition, the recruit-
ment of lysosomes to the parasitophorous vacuole and
the subsequent escape from the parasitophorous vacuole/
phagolysosomes were not impaired in CK18 RNAi-treated
cells.
Once the amastigotes were in the cytoplasm of HeLa cells
treated with CK18 RNAi, the growth of parasites of two
different strains (Y or CL-Brener) was severely arrested.
Co-localization studies support the hypothesis of close
contact between amastigotes of the Y strain and CK18 in
the HeLa cell cytoplasm. Because HeLa cells have CK8, it
would be possible that it replace CK18. However, we
observed that the level of expression of CK8 was also
reduced following CK18 RNAi treatment of HeLa cells
(Fig. 2).
It would be possible that RNAi to CK-18 inhibited the
expression of parasites CK. However, gene silencing with
RNAi in T. cruzi can not be performed due to the fact that
this system is not present in these cells. Two main points
have been discussed to explain this absence: (1) the AGO1
homologue (protein belonging to RISC and showed to be
present on Trypanosoma brucei, [27]) or any other gene
involved in RNAi pathway are absent; (2) at some point
during the evolution, the parasite acquired an RNAi
repressor as a reflection of a successful viral attack
(reviewed [28]).
Cytokeratins are the most abundant structural proteins of
epithelial cells, organized as heterodimers and forming a
network of 10–12 nm wide intermediate filaments (IF).
HeLa cells express CK8 and CK18. The IF maintains cell
integrity, protects from environmental stress and regulates
cytoplasmic protein availability, leading to the regulation
of cell signaling. Indeed, CK18 alterations may be one of
several anti-apoptotic events [29]. However, in our exper-
iment, we observed no significant induction of apoptosis
in HeLa cells in the absence of CK18. It has been shown
CK18 RNAi treatment inhibit amastigotes multiplication in  HeLa cells Figure 6
CK18 RNAi treatment inhibit amastigotes multipli-
cation in HeLa cells. HeLa cells were left untreated or 
treated with CK18 RNAi or control RNAi. After 24 h, cells 
were infected with culture trypomastigotes of the Y strain of 
T. cruzi. Forty-eight hours post infection, we estimated: (A) 
The frequency of infected HeLa; (B) The number of parasites 
per 100 cells; (C) The frequency of infected cells with 1–5 or 
> 5 parasites. Bars represent the average of triplicate cul-
tures ± SD. Asterisks denote significantly lower numbers 
when compared to non-transfected or control RNAi (P < 
0.01).
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that CK18 but not CK8 is a substrate for caspase digestion
during the course of epithelial cell apoptosis, and the acti-
vation of caspase 3 is strictly dependent on the presence of
CK18 [30]. Based on that, we can speculate that the
reduced levels of CK18 caused by CK18 RNAi, could affect
the caspase 3 activation, that in the absence of its substrate
would be in the inactive form and consequently the cell
would not enter in the apoptosis process.
Another interesting question is how the interaction with
CK18 or CK8 facilitates the multiplication of amastigotes.
Because very little is known about the parasite require-
ments for amastigote proliferation in the host cell cyto-
plasm, this question has no simple answer. Because
amastigotes are intracellular forms and need to prolifer-
ate, it is possible that they bind to CK18. The binding to
CK18 would initiate a signaling cascade within the para-
site, recruiting the signaling proteins required for its mul-
tiplication. Our hypothesis is based on previous
observations. Goto et al. [30] described the induction of
growth of Leishmania (Leishmania) mexicana amastigotes
and promastigotes by insulin-like growth factor I (IGF-I).
IGF-I from the host binds to a single-site receptor on both
promastigote and amastigote forms of Leishmania, initi-
Analysis of amastigote replication on CK18 RNAi treated HeLa cells infected with different T. cruzi strains Figure 7
Analysis of amastigote replication on CK18 RNAi treated HeLa cells infected with different T. cruzi strains. 
HeLa cells were left untreated (A and D), or were transfected with control RNAi (B and E), or CK18 RNAi (C and F). These 
cells were then infected with tissue culture trypomastigotes of the Y (A-C) or CL-Brener (D-F) strains of T. cruzi. After 48 h, 
cells were fixed and stained with Giemsa. Magnification bar = 20 μM.
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Table 1: RNAi – medited knockdown of CK18 inhibits intracellular multiplication of amastigotes of Y or CL-Brener strains
Parasite Strain % of infected cell Amastigotes/100 cells
Medium CK18 RNAi a CTR RNAi a Medium CK18 RNAi a CTR RNAi a
Y 32.0 ± 4.95 30.0 ± 3.53 28.0 ± 2.83 578 ± 11.36 142 ± 20.66b 497 ± 16.04
CL-Brener 33.0 ± 2.0 35.0 ± 4.16 33.0 ± 4.04 411 ± 14.57 176 ± 18.55b 406 ± 16.92
a HeLa cells were transiently transfected with CK18 or control RNAi 24 h earlier as described in Methods section. These cells were infected with 
culture trypomastigotes of Y or CL-Brener strain using the parasite per cell ratio of 10:1 or 5:1 respectively. The number of intracellular 
amastigotes was estimated 48 h post-infection and the results are expressed as average of triplicates ± SD. This experiment was performed 3 times 
with similar results.
b The number of amastigotes in cultures containing medium or RNAi control are lower than the number of amastigotes in cultures containing 
Medium with control RNAi (P < 0.01 in all cases, One Way Anova).BMC Cell Biology 2008, 9:68 http://www.biomedcentral.com/1471-2121/9/68
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ating a signaling cascade [31]. IGF-I induced tyrosine
phosphorylation of parasite proteins with different
molecular weights in both forms of the parasite; it
increased the DNA synthesis rate and consequently, the
number of parasites inside the host cells rose [30]. The
putative signaling pathway originated from the interac-
tion between CK18 from the host cell and a putative par-
asite receptor is currently under investigation.
Our work is the third example of the use of RNAi technol-
ogy to characterize proteins that might be involved in T.
cruzi interaction with host cells. This approach proved to
be feasible in small target projects and it has been used in
pilot studies to conduct a genome-wide RNAi screen. We
have already initiated this type of study in partnership
with a private research institute. In the case of other non-
neglected pathogens such as Mycobacteria and HIV, this
approach is already in use [31-35].
Although the RNAi knockdown of host cells is being per-
formed only to a limited extent and in vitro, it may be fea-
sible to use RNAi technology to inhibit pathogen
multiplication in localized areas of a patient's body. In the
case of T. cruzi, this strategy might be useful, along with
other forms of local treatment such as the recently devel-
oped cell therapy [36,37].
Conclusion
The data presented here demonstrate that CK18-RNAi
treatment of HeLa cells does not affect T. cruzi trypomas-
tigotes invasion, the recruitment of lysosomes to the par-
asitophorus vacuole and the subsequent escape to the cell
cytoplasm. On the other hand, CK18 expression in HeLa
cells is important for the intracellular amastigotes multi-
plication of Y and CL-Brener strains. The elucidation of
mechanisms used by the parasites for its replication inside
the cell cytoplasm may lead to new paths for drug inter-
vention.
Methods
Parasites and cells
Trypomastigotes of T. cruzi of Y strain were obtained from
Dr. S. Schenkman (Universidade Federal de São Paulo).
CL-Brener parasites were obtained from Dr. N. Yoshida
(Universidade Federal de São Paulo). Parasites were main-
tained in cultured LLC-MK2 cells (also provided by Dr. S.
Schenkman). All strains were molecularly typed based on
small subunit rDNA sequences to confirm their origin
[35]. These strains belong to diverse lineages. Y and CL-
Brener strains are T. cruzi II and a hybrid I/II, respectively.
HeLa cells provided by Dr. N. Yoshida were used for the in
vitro experiments.
Generation of double stranded RNAi and cell-transfections
The oligonucleotide retriever program available at http://
www.invitrogen.com/rnai was used to generate sequences
Co-staining of intracellular amastigotes and CK18 in infected  HeLa cells Figure 8
Co-staining of intracellular amastigotes and CK18 in 
infected HeLa cells. HeLa cells were left untreated 
(Medium, A) or transiently transfected with control RNAi (B) 
or CK18 RNAi (C). After 24 h, cells were infected with tis-
sue culture trypomastigotes of the Y (A-C) strain. After 48 h, 
the cells were fixed, and stained for CK18 (green fluores-
cence), parasites (red fluorescence), and DAPI (blue). Images 
were obtained individually and merged. Magnification bar = 
80 μM.
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that code for RNAi of CK18 gene [GenBank: BC000180].
The oligonucleotides were synthesized (Stealth RNAi –
Invitrogen). As negative control, we used Universal RNAi
Stealth (Invitrogen, Nr lot 316294). HeLa cells were used
for transfection experiments. Twenty four h before trans-
fection, 1.5 × 104 cells were adhered to 24-well Costar
plates in a final volume of 0.5 mL at 30–50% confluency.
For transfection, 1 μL of Lipofectamin 2000 (Invitrogen)
was admixed with RNAi (20 pmol) in a total volume of
100  μL of plain RPMI medium (Invitrogen) without
serum or antibiotics. After 20 min rt, the mixture was
added to the cells and incubated for 6 h. Transfection
medium was removed and complete RPMI medium
(cRPMI, RPMI supplemented with 10 mM HEPES, 24 mM
sodium bicarbonate, 10% (vol/vol) of Fetal Bovine Serum
(FBS, all purchased from Invitrogen), 100 U/ml of penicil-
lin and streptomycin (Sigma)) were added.
Double strand RNAi sequences specific for CK18 gene
used were:
i) RNAi: 5'-GCCCGUCUUGCUGCUGAUGACUUUA-3'
(sense)
ii) RNAi: 5'-UAAAGUCAUCAGCAGCAAGACGGGC-3'
(anti-sense)
Real-time PCR quantification of CK18 transcripts
HeLa cells (107) were washed with cRPMI medium and
resuspended in the final volume of 0.25 mL. To this solu-
tion, we added 0.75 mL of Trizol (Invitrogen). Purified
total RNA were treated with RNAse-free DNAse. First-
strand cDNA was synthesized from 2 μg of purified total
RNA using the ThermoScript RT-PCR System (Invitrogen)
following the specifications provided by the manufac-
turer. Primers for reverse transcriptase reaction were oligo-
DT provided with the kit. cDNAs were used for CK18 tran-
script quantification performed with the aid of the
Applied Biosystems 7300 Real-Time PCR System. Reac-
tions were performed in triplicate using SYBR Green (Inv-
itrogen) in a final volume of 25 μl following the
specifications provided by the manufacturer. The cycling
conditions were 95°C for 2 min, 45 cycles of 95°C for 15
s, 60°C for 30 s and 72°C for 30 s. Melting curve analysis
was performed heating the PCR products to 95°C and
cooled down to 60°C. The quantity of RPL13 (housekeep-
ing) transcript in each sample was used to normalize the
amount of CK18 transcripts. The primers sequences used
for quantitative Real-time PCR were:
i) RPL13A: 5'-CCTGGAGGAGAAGAGGAAAGAGA-
3'(sense);
ii) RPL13A: 5'-TTGAGGACCTCTGTGTATTTGTCAA-
3'(anti-sense);
iii) CK18: 5'-AATGGGAGGCATCCAGAACGAGAA-
3'(sense);
iv) CK18: 5'-TTCTTCTCCAAGTGCTCCCGGATT-3'(anti-
sense).
Immunoblotting
HeLa cells (106) grown in 6 wells plates (Costar), trans-
fected or not with RNAi, were washed with cold PBS twice
and lysed in the presence of lysis buffer prepared with
sodium deoxicholate (0.25%, w/vol), HEPES (500 mM),
NaCl (150 mM), Triton X-100 (1%, vol/vol), EGTA (20
mM), MgCl2 (1.5 mM), ortovanadate (100 mM), apro-
tinin (1 mg/mL), leupeptin (1 mg/mL), PMSF (100 mM),
NaF (50 mM) and NaPyr (10 mM). Cell lysates were kept
at -80°C for 24 h, centrifuged 15,000 g for 10 min and the
supernatants were collected. Their protein content was
estimated by the Bradford reagent (BioRad) and used to
load SDS-PAGE. The volume equivalent to 106 lysed HeLa
cells (~60 μg) were loaded onto 10% SDS-PAGE. Proteins
were transferred to nitrocellulose membrane (Millipore)
for 1 h at 100 V. Blocking solution was TBS containing
0.1% (vol/vol) of Tween and 2.5% (weight/vol) Bovine
serum albumin (TBS-T/BSA) for 2 h at rt. After washed for
15 min with TBS-T, a monoclonal antibody to CK18 (Cal-
biochem) or β-actin (Sigma) were added at dilutions of
1:1,000 or 1:6,000, respectively, and incubated for 16 h at
4°C. After washes with TBS-T, peroxidase labeled goat
anti-mouse IgG (Invitrogen) diluted 1:2,500 was added
for 1 h at rt. After extensive washes, membranes were
developed by enhanced-chemiluminescence system
SuperSignal (PIERCE) and exposed to Hyperfilm
(Kodak).
Cellular infection assays
HeLa cells (1.5 × 104) were plated in cRPMI medium in 24
well plates (Costar) containing 13-mm round coverslips
at 37°C in a humidified atmosphere containing 5% CO2.
These cells were transfected or not 24 h earlier with CK18-
RNAi or control RNAi as described above. Parasite pene-
tration to HeLa cells was evaluated at 2 h. Ten parasites per
target cells was used for infection with trypomastigotes of
the Y strain. In the case CL-Brener strain, we used 5 trypo-
mastigotes per HeLa cell. To determine the number of par-
asites that invaded HeLa cells, we fixed them with a
paraformaldehyde solution (2% vol/vol) for 30 min at rt.
After washed twice with PBS and blocked with PBS-FBS
(10% vol/vol) for 1 h a 37°C, we added rabbit polyclonal
antibodies specific to T. cruzi (serum dilution of 1:200)
followed by secondary staining with CY3-labeled goat
anti-rabbit (1:50, Sigma) and DAPI (diluted 1:50, Invitro-
gen Molecular Probes). To estimate the number of para-
sites inside LAMP-1+  vacuoles, cells infected at the
indicated timing were fixed and subject to immunofluo-
rescence assay (IFA) using a MAb specific for humanBMC Cell Biology 2008, 9:68 http://www.biomedcentral.com/1471-2121/9/68
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LAMP-1 (1:500, HDB, Hybridome) and DAPI. Coverslips
were washed in PBS, mounted and visualized under a flu-
orescence microscopy (Nikon E600). The number of
internalized parasites was obtained by subtracting the
number of bound CY3-fluorescent parasites from the total
number of DAPI-stained kinetoplast DNA parasites per
100 HeLa cells. Parasite multiplication within cells was
evaluated at 48 h using Giemsa stained coverslips and a
conventional light microscope (Olympus CH30). The
percentage inhibition of the amastigote growth was esti-
mated by the formula: Number of amastigotes per 100
control cells – frequency of infected control cells/Number
of amastigotes per 100 RNAi-treated cells – frequency of
RNAi-treated infected cells. Infection assays using HeLa
cells were done in triplicate and experiments were
repeated in three or more occasion with similar results.
Staining for CK8, CK18, CK19 and double-staining of 
parasites and CK18 in HeLa cells
HeLa cells (1.5 × 104) were plated in cRPMI medium on
24 well plates containing 13-mm round coverslips at
37°C in a humidified atmosphere containing 5% CO2.
These cells were infected with culture trypomastigotes of Y
strain. The number of parasites per HeLa cell was 10:1,
respectively. After 48 h, the cells were washed with PBS,
fixed in paraformaldehyde solution (2% vol/vol) for 30
min at rt. After washed twice, the cells were permeabilized
with PBS containing Triton X-100 (1% vol/vol) and
blocked with PBS/BSA (3% weight/vol) for 40 min at rt.
The cells were then stained with a MAb to CK8, CK18,
CK19 (all purchased from Santa Cruz Biotechnology), or
to CK18 (Calbiochem) diluted 1:40 in PBS/BSA for 1 h in
a humid environment. Coverslips were washed with PBS
and FITC-labeled anti-mouse IgG (1:100) added for 1 h.
Coverslips were washed again and stained with the rabbit
polyclonal antibodies specific for T. cruzi antigens (pro-
vided by Dr. S. Schenkman) diluted 1:100 for 1 h. After
washes with PBS, the coverslips were incubated with CY3-
labeled anti-rabbit IgG (Sigma) diluted 1:50 in PBS/BSA
containing DAPI for 1 h. Coverslips were washed,
mounted with buffered glycerin and observed on Confo-
cal Microscope.
Staining with Annexin-V-FITC/PI
HeLa cells (1.5 × 105) were transiently transfected or not
24 h earlier with CK18-RNAi or control RNAi as described
above. After that period, cell culture medium was
exchanged and the cells cultured for additional 10 h in
cRPMI medium. The cells were collected, washed in cold
PBS and resuspended to a final concentration of 1 × 105/
ml in ligation buffer. 1 × 104 cells were labeled with FITC-
conjugated Annexin-V (1:20) and propidium iodine (PI,
1:20 both from BD Biosciences Pharmingen) for 15 min
in the dark. Cells were fixed with paraformaldehyde solu-
tion (2% weight/vol) and analyzed by fluorescence-acti-
vated cell sorting using FACSCanto (BD) and the software
FlowJo (FlowJo).
Statistical analysis
Values were compared by One-Way Anova followed by
Tukey HSD tests available at the site http://faculty.vas
sar.edu/lowry/VassarStats.html. Differences were consid-
ered significant when the P value was < 0.05.
Abbreviations
CK18: cytokeratin 18; CK19: cytokeratin 19; CK8: cytoker-
atin 8; RNAi: RNA interference; ASP-2: amastigote surface
protein-2; PI: propidium iodine; IFA: immunofluores-
cence assay; IF: intermediate filaments; LLC-MK2: mon-
key rhesus kidney cell.
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